SCHEMBL6420784

SCHEMBL6420784

Brc1ccc(Nc2nc3nonc3nc2NN=Cc2ccco2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.48
KMT2A Q03164 8/20 0.48
SMN1; SMN2 Q16637 7/20 0.48
MEN1 O00255 7/20 0.48
GAA P10253 6/20 0.48
NPC1 O15118 5/20 0.48
RAB9A P51151 4/20 0.48
KDM4E B2RXH2 4/20 0.48
MAPK1 P28482 2/20 0.48
PKM P14618 1/20 0.44
NPSR1 Q6W5P4 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
TDP1 Q9NUW8 5/20 0.40
ALDH1A1 P00352 4/20 0.40
LMNA P02545 2/20 0.40
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
HTT P42858 1/20 0.40
MAOB P27338 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6508259 1.00 MAPT (0.48) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL6421048 0.90 GAA (0.49) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL3055383 0.90 GAA (0.49) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL6417007 0.89 MAPT (0.51) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL6417000 0.89 MAPT (0.51) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL6414713 0.84 SMN1; SMN2 (0.50) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL6431993 0.81 SMN1; SMN2 (0.51) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL3058312 0.81 SMN1; SMN2 (0.48) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL3058317 0.81 SMN1; SMN2 (0.48) MAPTKMT2ASMN1; SMN2MEN1GAA
SCHEMBL6431990 0.81 SMN1; SMN2 (0.51) MAPTKMT2ASMN1; SMN2MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005051381-A1 Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) BIOVITRUM AB (SE) 2005-06-09 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885KMT2A 3640/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.